# OnCo record merck-kgaa (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/merck-kgaa/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "merck-kgaa" ;
  schema:name "Merck KGaA (EMD Serono)"@en ;
  schema:alternateName "EMD Serono"@en, "EMD Serono, Inc."@en, "EMD Serono Research & Development Institute, Inc."@en, "Merck Healthcare KGaA"@en, "Merck KGaA, Darmstadt, Germany"@en, "Merck Serono"@en ;
  schema:description "Merck KGaA of Darmstadt, which trades as EMD Serono in North America, sells the anti-PD-L1 antibody avelumab, cetuximab outside the United States and the MET inhibitor tepotinib, and bought SpringWorks Therapeutics in 2025 to add nirogacestat and mirdametinib for rare tumours."@en ;
  schema:url <https://onco.cc/companies/merck-kgaa/>, <https://www.merckgroup.com> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Merck_Group> ;
  owl:sameAs <http://www.wikidata.org/entity/Q156959> ;
  schema:citation <https://www.merckgroup.com>, <https://www.sec.gov/Archives/edgar/data/1773427/000110465925064445/tm2519396d1_8k.htm>, <https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0401/2025040100115.pdf>, <https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications> ;
  onco:tag "fda-oce-applicant" ;
  schema:addressCountry "DE" ;
  onco:cancers <https://onco.cc/cancers/urothelial/>, <https://onco.cc/cancers/merkel-cell-carcinoma/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/desmoid-tumour/>, <https://onco.cc/cancers/tenosynovial-giant-cell-tumour/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/>, <https://onco.cc/fronts/targeted-therapy/> ;
  onco:drugs <https://onco.cc/drugs/avelumab/>, <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/capmatinib-tepotinib/>, <https://onco.cc/drugs/nirogacestat/>, <https://onco.cc/drugs/mirdametinib/>, <https://onco.cc/drugs/precemtabart-tocentecan/>, <https://onco.cc/drugs/pimicotinib/> ;
  onco:companies <https://onco.cc/companies/springworks/>, <https://onco.cc/companies/abbisko/> ;
  onco:trials <https://onco.cc/trials/nct02864992/>, <https://onco.cc/trials/nct06710132/>, <https://onco.cc/trials/nct03815643/>, <https://onco.cc/trials/nct05327530/> .